The experiences of patients with pulmonary. arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons

被引:11
|
作者
Hall, Heather [1 ]
Cote, Joanne [2 ]
McBean, Althea [2 ]
Purden, Margaret [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Sch Nursing, Ctr Nursing Res, Montreal, PQ H3T 1E2, Canada
[2] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ H3T 1E2, Canada
来源
HEART & LUNG | 2012年 / 41卷 / 01期
关键词
Epoprostenol; Pulmonary arterial hypertension; Qualitative; Resilience; Support persons; Technology; QUALITY-OF-LIFE; RESILIENCE; THERAPY; HOME; PROSTACYCLIN;
D O I
10.1016/j.hrtlng.2011.05.007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH). The study objective was to describe the experiences of patients and their support persons adjusting to PAH and continuous intravenous epoprostenol. METHODS: A qualitative descriptive design with semistructured interviews was conducted jointly with the patient and his/her support person. Seven patients and their support persons (spouse, child, friend) were included. RESULTS: Patients demonstrated personal growth and resilience as they adapted to PAH. Four patient themes emerged: initial shock, figuring it out, giving life, and ongoing struggles. Themes specific to the support person included "their life is in my hands," pressure to perform, and continuation of my role. CONCLUSION: Nurses may assist these patients and support persons by teaching technical skills, problem-solving and troubleshooting strategies, mobilizing social support, and providing opportunities to reflect on lifestyle changes and long-term adjustment to PAH. Cite this article: Hall, H., Cote, J., McBean, A., & Purden, M. (2012, JANUARY/FEBRUARY). The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons. Heart & Lung, 41(1), 35-43. doi:10.1016/j.hrtlng.2011.05.007.
引用
收藏
页码:35 / 43
页数:9
相关论文
共 50 条
  • [31] Effects of continuous intravenous epoprostenol therapy on advanced primary pulmonary hypertension in Taiwanese patients
    Hsu, HH
    Chen, JS
    Kuo, SH
    Chiang, FT
    Ko, WJ
    Kuo, SW
    Huang, SC
    Lee, YC
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2005, 104 (01) : 60 - 63
  • [32] Adverse effects of long-term prostacyclin (Flolan) continuous infusion for Pulmonary Hypertension
    Kruger, ME
    Wirth, JA
    Vogel, B
    Caldwell, EJ
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (03) : A162 - A162
  • [33] Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment
    Petkov, V
    Ziesche, R
    Mosgoeller, W
    Schenk, P
    Vonbank, K
    Stiebellehner, L
    Raderer, M
    Brunner, C
    Kneussl, M
    Block, LH
    THORAX, 2001, 56 (09) : 734 - 736
  • [34] Intravenous epoprostenol therapy in the treatment of pulmonary arterial hypertension: the Singapore experience
    Choo, J.
    Yap, J.
    Aidila, Ismail
    Lim, C. L.
    Sumathy, P.
    Ruan, W.
    Sewa, D. W.
    Phua, G. C.
    Hong, C.
    Low, A. H. L.
    Lim, S. T.
    Tan, J. L.
    EUROPEAN HEART JOURNAL, 2022, 43
  • [35] Efficacy Of Intravenous Epoprostenol For Pulmonary Arterial Hypertension In 2 Treatment Eras
    Delcroix, M.
    Wuyts, W.
    Vandevelde, E.
    Koen, J.
    De Clippel, M.
    Baptista, R.
    Vachiery, J. -L.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [36] THERMOSTABLE INTRAVENOUS EPOPROSTENOL FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - A TRANSITION STUDY
    MacLellan, A.
    Carson, K.
    Brewis, M.
    Johnson, M.
    McGettrick, M.
    McCaughey, P.
    Crozier, A.
    Thomson, R.
    Church, C.
    THORAX, 2019, 74 : A152 - A153
  • [37] Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy
    Myers, SA
    Ahearn, GS
    Selim, MA
    Tapson, VE
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (01) : 98 - 102
  • [38] Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease
    Bakst, AE
    Gaine, SP
    Rubin, LJ
    CHEST, 1999, 116 (04) : 1127 - +
  • [39] Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension
    Mouratoglou, Sophia Anastasia
    Patsiala, Anthoula
    Feloukidis, Christos
    Karvounis, Haralambos
    Giannakoulas, George
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 187 - 189
  • [40] Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center
    Shirai, Yuichiro
    Yasuoka, Hidekata
    Takeuchi, Tsutomu
    Satoh, Toru
    Kuwana, Masataka
    MODERN RHEUMATOLOGY, 2013, 23 (06) : 1211 - 1220